Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01625650 · ClinicalTrials.gov registry record

Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study

A clinical trial of Rheumatoid Arthritis, sponsored by CorEvitas.

Completed
Registry status
2,795
Enrollment target
1
Study location

NCT01625650 is a study of Rheumatoid Arthritis that has completed, run by CorEvitas. The registered enrollment target is 2,795 participants, below the 4,676-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01625650, a study of Rheumatoid Arthritis, has completed, sponsored by CorEvitas.

COMPLETED
Registry status
2,795 participants
Enrollment target
1
Study location

Study Summary

The CORRONA CERTAIN Sub-study of the Consortium of Rheumatology Researchers of North America, Inc. is a Sub-study of the CORRONA Data Collection Program. The CERTAIN Sub-study is designed to systematically collect and document use patterns, effectiveness, comparative effectiveness and safety of biologic agents used in the management of Rheumatoid Arthritis (RA).

Conditions Studied

Study Locations (1)

New York

  • The Center For Rheumatoligy - Albany

Trial Details

FieldValue
Enrollment Target 2,795 participants
Start Date 2010-10
Est. Completion 2015-05

Sponsor

CorEvitas

13 total trials

What the Registry Record Tells You About NCT01625650

The ClinicalTrials.gov registry entry for NCT01625650 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,795 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,676-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (40% lower). The listed sponsor is CorEvitas, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.

NCT01625650 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01625650 about?

NCT01625650 is a clinical study titled "Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study". The CORRONA CERTAIN Sub-study of the Consortium of Rheumatology Researchers of North America, Inc. is a Sub-study of the CORRONA Data Collection Program. The CERTAIN Sub-study is designed to systematically collect and document use patterns, effectiveness, comparative effectiveness and safety of bio...

What is the current status of trial NCT01625650?

This trial is currently completed. The enrollment target is 2,795 participants. The study started on 2010-10. Estimated completion is 2015-05.

What conditions does trial NCT01625650 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

Who is sponsoring clinical trial NCT01625650?

This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01625650 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.